diucifon: contains 6-methyluracil & p,p-2,4-dihydroxy-6-methylpyrimidinyl-5-sulfonaminodiphenylsulfone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 122139 |
| SCHEMBL ID | 7995862 |
| MeSH ID | M0080567 |
| Synonym |
|---|
| diucifon |
| diucifone |
| brn 0956324 |
| p,p-bis(2,4-dioxy-6-methylpyrimidinyl-5-sulfonamido)diphenylsulfone |
| diutsifon |
| p,p-2,4-dioxy-6-methyl-pyrimidinyl-5-sulfonamino/diphenyl sulfone |
| 5-pyrimidinesulfonamide, n,n'-(sulfonyldi-4,1-phenylene)bis(1,2,3,4-tetrahydro-6-methyl-2,4-dioxo- |
| AKOS003678711 |
| 34941-71-4 |
| n,n'-(sulfonyldibenzene-4,1-diyl)bis(6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-sulfonamide) |
| 6-methyl-n-[4-[4-[(6-methyl-2,4-dioxo-1h-pyrimidin-5-yl)sulfonylamino]phenyl]sulfonylphenyl]-2,4-dioxo-1h-pyrimidine-5-sulfonamide |
| h2j64m9k8z , |
| unii-h2j64m9k8z |
| diuciphone |
| STL264278 |
| SCHEMBL7995862 |
| diyon |
| Q5283748 |
| DTXSID90956401 |
| n,n'-[sulfonyldi(4,1-phenylene)]bis(2,4-dihydroxy-6-methylpyrimidine-5-sulfonamide) |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 26 (72.22) | 18.7374 |
| 1990's | 7 (19.44) | 18.2507 |
| 2000's | 3 (8.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (15.56%) | 5.53% |
| Reviews | 1 (2.22%) | 6.00% |
| Case Studies | 1 (2.22%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 36 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Substance | Relationship Strength | Studies | Trials | Classes | Roles |
|---|---|---|---|---|---|
| uracil 2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder | 7.98 | 36 | 7 | pyrimidine nucleobase; pyrimidone | allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite |
| dapsone [no description available] | 3.35 | 1 | 1 | substituted aniline; sulfone | anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug |
| isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC). | 2.42 | 2 | 0 | carbohydrazide | antitubercular agent; drug allergen |
| ketotifen Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.. ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect. | 1.96 | 1 | 0 | cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound | anti-asthmatic drug; H1-receptor antagonist |
| erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively. | 1.96 | 1 | 0 | cyclic ketone; erythromycin | |
| levamisole Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine. | 3.21 | 6 | 0 | 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole | antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator |
| flumecinol flumecinol: liver microsomal drug metabolizing enzyme inducer | 1.96 | 1 | 0 | diarylmethane | |
| xymedon xymedon: nitrogen-containing heterocyclic compound; Russian patent; antiatherogenic; used for treatment of burns; used on varicose ulcer | 1.99 | 1 | 0 | ||
| dapsone, methyluracil drug combination [no description available] | 3.35 | 1 | 1 | ||
| bismuth Bismuth: A metallic element that has the atomic symbol Bi, and atomic number 83. Its principal isotope is Bismuth 209. | 1.96 | 1 | 0 | metal atom; pnictogen | |
| oxytetracycline, anhydrous Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae. | 1.96 | 1 | 0 | ||
| adimicin adimicin: contains oxytetracycline di-HCl & erythromycin propionate laurylsulfate; Russian drug | 1.96 | 1 | 0 | ||
| cyclic gmp Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine. | 1.96 | 1 | 0 | 3',5'-cyclic purine nucleotide; guanyl ribonucleotide | Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite |
| rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) | 1.96 | 1 | 0 | cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion | angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor |
| concanavalin a Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures. | 2.37 | 2 | 0 |
| Condition | Indicated | Relationship Strength | Studies | Trials |
|---|---|---|---|---|
| Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma. | 0 | 5.17 | 6 | 2 |
| Pulmonary Consumption [description not available] | 0 | 3.08 | 5 | 0 |
| Pneumonia Infection of the lung often accompanied by inflammation. | 0 | 5.17 | 6 | 2 |
| Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung. | 0 | 3.08 | 5 | 0 |
| Disease Exacerbation [description not available] | 0 | 2.02 | 1 | 0 |
| Dermatitis, Eczematous [description not available] | 0 | 4.04 | 3 | 1 |
| Eczema A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed). | 0 | 4.04 | 3 | 1 |
| Convalescence The period of recovery following an illness. | 0 | 3.75 | 2 | 1 |
| Acute Disease Disease having a short and relatively severe course. | 0 | 4.04 | 3 | 1 |
| Chronic Illness [description not available] | 0 | 4.04 | 3 | 1 |
| Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). | 0 | 4.04 | 3 | 1 |
| Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI. | 0 | 3.75 | 2 | 1 |
| Hansen Disease [description not available] | 0 | 3.76 | 2 | 1 |
| Leprosy A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid. | 0 | 3.76 | 2 | 1 |
| Palmoplantaris Pustulosis [description not available] | 0 | 3.34 | 1 | 1 |
| Sclerosis, Systemic [description not available] | 0 | 4.31 | 2 | 2 |
| Dermatoses [description not available] | 0 | 8.34 | 1 | 1 |
| Duhring Disease [description not available] | 0 | 3.34 | 1 | 1 |
| Dermatitis Herpetiformis Rare, chronic, papulo-vesicular disease characterized by an intensely pruritic eruption consisting of various combinations of symmetrical, erythematous, papular, vesicular, or bullous lesions. The disease is strongly associated with the presence of HLA-B8 and HLA-DR3 antigens. A variety of different autoantibodies has been detected in small numbers in patients with dermatitis herpetiformis. | 0 | 3.34 | 1 | 1 |
| Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. | 0 | 3.34 | 1 | 1 |
| Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA. | 0 | 4.31 | 2 | 2 |
| Skin Diseases Diseases involving the DERMIS or EPIDERMIS. | 0 | 3.34 | 1 | 1 |
| Recrudescence [description not available] | 0 | 4.04 | 3 | 1 |
| Pyoderma Any purulent skin disease (Dorland, 27th ed). | 0 | 6.96 | 1 | 0 |
| Cholangitis Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both. | 0 | 1.98 | 1 | 0 |
| Atopic Hypersensitivity [description not available] | 0 | 1.99 | 1 | 0 |
| Antibody Deficiency Syndrome [description not available] | 0 | 2.38 | 2 | 0 |
| Immunologic Deficiency Syndromes Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral. | 0 | 2.38 | 2 | 0 |
| Infections, Orthomyxoviridae [description not available] | 0 | 1.98 | 1 | 0 |
| Orthomyxoviridae Infections Virus diseases caused by the ORTHOMYXOVIRIDAE. | 0 | 1.98 | 1 | 0 |
| Infections, Pseudomonas [description not available] | 0 | 1.97 | 1 | 0 |
| Burns Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like. | 0 | 1.97 | 1 | 0 |
| Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. | 0 | 1.97 | 1 | 0 |
| Infection [description not available] | 0 | 8.36 | 1 | 1 |
| Pus [description not available] | 0 | 3.36 | 1 | 1 |
| Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases. | 0 | 8.36 | 1 | 1 |
| Athlete's Foot [description not available] | 0 | 1.97 | 1 | 0 |
| Tinea Pedis Dermatological pruritic lesion in the feet, caused by Trichophyton rubrum, T. mentagrophytes, or Epidermophyton floccosum. | 0 | 1.97 | 1 | 0 |
| Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. | 0 | 1.97 | 1 | 0 |
| Lymphocytopenia [description not available] | 0 | 1.96 | 1 | 0 |
| Lymphopenia Reduction in the number of lymphocytes. | 0 | 1.96 | 1 | 0 |
| Asthma, Bronchial [description not available] | 0 | 1.97 | 1 | 0 |
| Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). | 0 | 6.97 | 1 | 0 |
| Boils [description not available] | 0 | 3.35 | 1 | 1 |
| Sinus Infections [description not available] | 0 | 3.35 | 1 | 1 |
| Sinusitis Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES. | 0 | 3.35 | 1 | 1 |
| Rheumatoid Arthritis [description not available] | 0 | 8.35 | 1 | 1 |
| Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. | 0 | 3.35 | 1 | 1 |
| Infections, Chlamydia [description not available] | 0 | 1.96 | 1 | 0 |
| Female Genital Diseases [description not available] | 0 | 1.96 | 1 | 0 |
| Genital Diseases, Male Pathological processes involving the male reproductive tract (GENITALIA, MALE). | 0 | 1.96 | 1 | 0 |
| Eperythrozoonosis [description not available] | 0 | 1.96 | 1 | 0 |
| Chlamydia Infections Infections with bacteria of the genus CHLAMYDIA. | 0 | 1.96 | 1 | 0 |
| Genital Diseases, Female Pathological processes involving the female reproductive tract (GENITALIA, FEMALE). | 0 | 1.96 | 1 | 0 |
| Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA. | 0 | 1.96 | 1 | 0 |
| Disease, Pulmonary [description not available] | 0 | 1.96 | 1 | 0 |
| Lung Diseases Pathological processes involving any part of the LUNG. | 0 | 1.96 | 1 | 0 |
| Ataxia Telangiectasia Syndrome [description not available] | 0 | 1.96 | 1 | 0 |
| Ataxia Telangiectasia An autosomal recessive inherited disorder characterized by choreoathetosis beginning in childhood, progressive CEREBELLAR ATAXIA; TELANGIECTASIS of CONJUNCTIVA and SKIN; DYSARTHRIA; B- and T-cell immunodeficiency, and RADIOSENSITIVITY to IONIZING RADIATION. Affected individuals are prone to recurrent sinobronchopulmonary infections, lymphoreticular neoplasms, and other malignancies. Serum ALPHA-FETOPROTEINS are usually elevated. (Menkes, Textbook of Child Neurology, 5th ed, p688) The gene for this disorder (ATM) encodes a cell cycle checkpoint protein kinase and has been mapped to chromosome 11 (11q22-q23). | 0 | 1.96 | 1 | 0 |
| Empyema, Gall Bladder [description not available] | 0 | 1.96 | 1 | 0 |
| Cholecystitis Inflammation of the GALLBLADDER; generally caused by impairment of BILE flow, GALLSTONES in the BILIARY TRACT, infections, or other diseases. | 0 | 1.96 | 1 | 0 |
| Great Pox [description not available] | 0 | 1.96 | 1 | 0 |
| Latent Stage Syphilis [description not available] | 0 | 1.96 | 1 | 0 |
| Syphilis A contagious venereal disease caused by the spirochete TREPONEMA PALLIDUM. | 0 | 1.96 | 1 | 0 |